Northwest Bio allegations prompt top U.K. investor to call for independent probe

Neil Woodford has invested $95 million in Northwest Biotherapeutics ($NWBO) and its controversial therapeutic cancer vaccine over the past year. And now that he has bought up 28% of the company's stock, he's pushing hard for an independent investigation into allegations of financial impropriety that have been in circulation since before he took his first big stake in the biotech. More from FierceBiotech

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.